Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post Transplant Cyclophosphamide for Allogeneic HSCT in Hematological Malignancies
NCT01349101Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Feb 2011
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cyclophosphamide in hematological malignancies, sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Feb 2011; status: completed.
02
Drugs
cyclophosphamide
03
Conditions
hematological malignancies
Beyond the preview
Go deeper on NCT01349101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01349101.